These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15000298)

  • 21. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
    Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
    Pu Q; Amiri F; Gannon P; Schiffrin EL
    J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
    Floras JS
    Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
    Elmarakby AA; Morsing P; Pollock JS; Pollock DM
    Vascul Pharmacol; 2003 Dec; 40(5):253-9. PubMed ID: 15259792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
    Rossi GP; Cavallin M; Rizzoni D; Bova S; Mazzocchi G; Agabiti-Rosei E; Nussdorfer GG; Pessina AC
    J Hypertens; 2002 Jul; 20(7):1451-9. PubMed ID: 12131544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D; Hoey A; Brown L
    Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat.
    Ferrario CM; Averill DB; Brosnihan KB; Chappell MC; Iskandar SS; Dean RH; Diz DI
    Kidney Int; 2002 Oct; 62(4):1349-57. PubMed ID: 12234305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
    Campese VM; Lasseter KC; Ferrario CM; Smith WB; Ruddy MC; Grim CE; Smith RD; Vargas R; Habashy MF; Vesterqvist O; Delaney CL; Liao WC
    Hypertension; 2001 Dec; 38(6):1342-8. PubMed ID: 11751715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
    Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
    Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.
    Chen HH; Cataliotti A; Burnett JC
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S15-21. PubMed ID: 11716801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension.
    Quaschning T; d'Uscio LV; Shaw S; Lüscher TF
    Hypertension; 2001 Apr; 37(4):1108-13. PubMed ID: 11304511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
    Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
    Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
    Pu Q; Schiffrin EL
    Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats.
    Ishimura K; Nishikimi T; Akimoto K; Ono H; Kangawa K; Matsuoka H
    J Hypertens; 2005 Dec; 23(12):2287-96. PubMed ID: 16269971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.